Zimmer Biomet Holdings (ZBH) Earnings Date & Reports
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery... Show more
ZBH is expected to report earnings to fall 3.35% to $2.02 per share on August 04
Zimmer Biomet (ZBH) First Quarter 2026 Earnings Recap: Revenue Beats, Guidance Raised
Key Takeaways
- Zimmer Biomet reported Q1 net sales of $2.087 billion, up 9.3% year-over-year on a reported basis, surpassing consensus estimates of approximately $2.07 billion.
- Adjusted diluted earnings per share (EPS) reached $2.09, a 15.5% increase from the prior year, beating analyst expectations around $1.86.
- GAAP diluted EPS was $1.22, up 34.1% year-over-year, with net earnings of $238.1 million.
- Strong growth in S.E.T. (Sports, Extremities, Trauma) segment at 19.5% reported and Technology & Data at 14.6%, offsetting softer core hips and knees.
- Full-year 2026 adjusted EPS guidance raised to $8.40-$8.55 from $8.30-$8.45, signaling confidence in execution.
- Shares fell about 5% post-earnings amid CFO transition announcement and concerns over organic growth.
Earnings Context and Why It Matters
Zimmer Biomet, a leader in musculoskeletal healthcare technologies, released its First Quarter 2026 results on April 28, amid ongoing sales force transformation and product innovation cycles. This report is pivotal as investors assess progress in core reconstructive franchises like hips and knees, which face procedural volume pressures, against high-growth areas such as robotics and S.E.T. With a market cap over $15 billion, strong execution here could reinforce ZBH's competitive edge in orthopedics, especially as peers navigate similar supply chain and reimbursement challenges. Healthy end markets and new product momentum underscore resilience in elective procedures post-pandemic.
Zimmer Biomet posted net sales of $2.087 billion for the First Quarter ended March 31, 2026, reflecting 9.3% reported growth, 6.8% constant currency growth (adjusted for foreign exchange effects), and 2.9% organic constant currency growth (excluding acquisitions and FX). This topped consensus revenue estimates of around $2.07 billion.
Adjusted diluted EPS came in at $2.09, up 15.5% year-over-year and exceeding expectations of $1.86, driven by sales leverage, gross margin expansion to 73.0% (adjusted), and operating margin of 27.3% (adjusted). GAAP EPS was $1.22, with net earnings of $238.1 million.
Segment-wise, S.E.T. surged 19.5% reported (1.6% organic), boosted by the Paragon 28 acquisition, while Hips grew 5.7% reported (3.2% organic) and Knees 4.5% reported (1.8% organic). Technology & Data, Bone Cement, and Surgical rose 14.6% reported. U.S. sales increased 8.6% to $1.209 billion, outpacing international growth of 10.3% to $877 million.
The company raised FY2026 adjusted diluted EPS guidance to $8.40-$8.55 (midpoint $8.475) from prior $8.30-$8.45, while holding revenue growth outlook steady at 1.0%-3.0% organic constant currency (excluding ~100 basis points from Paragon 28). Free cash flow growth expectations also lifted to 9%-11%.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research workflow.
Market Reaction and Investor Sentiment
Despite beating Q1 estimates, ZBH shares dropped approximately 5.3% in pre-market trading on April 29, reaching around $86.73, reflecting mixed investor reactions. The decline was linked to modest organic growth in core hips and knees segments, ongoing U.S. sales force overhaul, and a same-day announcement of CFO Christy McKenney's departure after 25 years, with interim leadership and search underway. Sentiment remains cautious heading into the transformation phase, though raised EPS guidance provided some offset.
Forward Outlook and Key Factors to Monitor
Zimmer Biomet's lifted EPS guidance signals operational momentum, supported by margin expansion and $250 million in Q1 share repurchases. Investors should watch progress on the go-to-market transformation, including sales force optimization, which could drive durable growth in reconstructive procedures.
Key segment dynamics merit attention: core Knees and Hips recovery amid procedure volumes, versus high-teens growth in S.E.T. and double-digit in robotics. The company targets over 200 robotics clinical hires by end-2027, alongside innovations like the G7 Acetabular System and Phantom Curved TTC Nail. Recent AAOS data presentations bolster the pipeline.
Broader factors include Paragon 28 integration impacts (~100bps drag on organic growth), free cash flow trajectory (now 9-11% growth), and macroeconomic influences on elective orthopedics. Upcoming catalysts: Q2 results in July, clinical milestones for mBôs robotic knee, and CFO search resolution. Balanced execution across end markets will shape trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a mobile application software
Industry MedicalNursingServices